Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests better smoking cessation plans for cancer patients

NCT ID NCT06218823

Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two different smoking cessation treatments in 52 adult cancer patients who had been diagnosed within the past 3 years. One group received a 12-week course of the medication varenicline plus 7 counseling calls tailored to cancer patients. The other group received a standard approach: 2 weeks of nicotine patches plus 3 brief counseling calls. The main goal was to see which treatment helped more patients stay smoke-free 26 weeks after their quit date.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
varenicline and nicotine patch
What this could lead to
If successful, this could identify a more effective way to help cancer patients quit smoking, improving their overall health and treatment outcomes.
What could go wrong
This is a small pilot study with only 52 participants, so results may not apply to all cancer patients. The treatments may not show a clear difference in effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

52 people

The number who actually took part.

Started

Mar 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Alive (per medical record) * Diagnosed with cancer in the past 3 years * Received care from a participating oncology clinic in the past year * Has a current tobacco use status * Does not have a preferred language other than English (missing language preference will be included). * Valid address that is not a correctional facility or residential treatment/care facility. * No flag for patient cognitive impairment, activated health care power of attorney, or other health care agent (e.g., legally authorized representative) in the EHR. The following additional inclusion criteria must be met for inclusion in the CET * Smoked combustible cigarettes in the past month. * Able to speak and understand English. * Willing to set a date to quit smoking in the next 60 days. * Willing to receive smoking treatment information. * Willing to complete study activities. Exclusion Criteria: * No current suicidal ideation. * Suicide attempt in the past year. * Currently receiving treatment for bipolar disorder, schizophrenia, schizoaffective disorder, or psychotic disorder. * Incarceration. * Unable to provide informed consent to treatment (i.e., cannot answer questions about study procedures or risks after hearing about the study).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm Smoking Cessation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Smoking cessation

Contacts and locations

Locations

  • UW Carbone Cancer Center

    Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.